ACADIA Pharmaceuticals (ACAD, Biotech) Stock Valuation & Fair Value
Significantly overvaluedACADIA Pharmaceuticals (ACAD, Biotech) trades at a current P/E of 23.7, about 152% above its historical normal valuation, with a forward growth estimate of 21.5% and a PEG of 1.10. Analysts' one-year estimates have been hit 27% of the time. Priced at its historical normal P/E of 9.4 on the same blended earnings, the 2026-11-06 close of $21.23 corresponds to about $8.42 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $21.23 at the Nov 6 close, 5.3% above the 20-day average ($20.16) and 7.1% below the 50-day ($22.86).
- RSI (14) at 51.8.
- 52-week range $18.62 to $30.57: the price is 30.6% below the high and 14.0% above the low.
The Street vs SeerForecast
Wall Street's mean price target for ACAD is $30.53 across 19 analysts, 43.8% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.
Valuation flags
- Overvalued by 152%
- Misses analyst estimates often (73%)
Verdict history
tickerseer's rating has been significantly overvalued since 2026-07-31.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, and the cheapest and dearest.
Show all 28 readings
Frequently asked questions
Is ACADIA Pharmaceuticals stock overvalued?
At a current P/E of 23.7 versus its historical normal P/E of 9.4, ACADIA Pharmaceuticals trades about 152% above its typical valuation, with a PEG of 1.10 on 21.5% forward growth. tickerseer currently rates it significantly overvalued.
What is ACADIA Pharmaceuticals's fair value and PEG?
ACADIA Pharmaceuticals trades at a current P/E of 23.7 against a historical normal P/E of 9.4, a PEG of 1.10, and a forward growth estimate of 21.5%. Priced at its historical normal P/E of 9.4 on the same blended earnings, the 2026-11-06 close of $21.23 corresponds to about $8.42 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of ACADIA Pharmaceuticals changed?
tickerseer's rating has been significantly overvalued since 2026-07-31.
What is the analyst price target for ACADIA Pharmaceuticals?
The mean Wall Street price target for ACADIA Pharmaceuticals is $30.53 across 19 analysts, 43.8% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.